GlassScriptPhysician profile
Peter S Trent
NPI 1871598110
$2,508.44
in general payments reported to CMS, 2019-2025
30 companies · $84.54 in 2025
The $84.54 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $324 · 2021: $169 · 2022: $280 · 2023: $68.08 · 2024: $342 · 2025: $84.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $579.97 | 2019 | |
| Horizon Therapeutics Plc | $292.12 | 2019-2022 | |
| Smith+Nephew, INC. | $261.70 | 2019-2024 | Journey II, Pico 7 |
| Zyla Life Sciences, INC. | $234.81 | 2019-2020 | |
| Depuy Synthes Sales INC. | $148.86 | 2019-2024 | Orthovisc |
| Curonix LLC | $135.96 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Bioventus LLC | $116.40 | 2019-2021 | |
| Orthofix Medical, INC. | $105.79 | 2019-2024 | Physio-Stim |
| Pacira Pharmaceuticals Incorporated | $94.32 | 2023-2025 | Exparel, Zilretta, Iovera |
| Melinta Therapeutics, LLC | $47.37 | 2019 | |
| Biocomposites INC | $43.58 | 2019 | |
| Integra Lifesciences Corporation | $43.31 | 2019-2022 | |
| Stryker Corporation | $38.17 | 2021 | |
| Tersera Therapeutics LLC | $35.43 | 2024 | Prialt |
| Medtronic, INC. | $34.05 | 2025 | Inceptiv |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $31.58 | 2023 | |
| Kerecis Limited | $29.69 | 2019 | |
| Fidia Pharma USA INC. | $29.01 | 2019-2021 | |
| Averitas Pharma INC. | $24.84 | 2025 | Qutenza |
| Pfizer INC. | $24.62 | 2019 | |
| Si-Bone, INC. | $20.92 | 2020 | |
| Amgen INC. | $18.20 | 2019 | |
| Daiichi Sankyo INC. | $17.27 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.10 | 2024 | Nuzyra |
| Convatec INC. | $15.40 | 2024 | |
| Medtronic USA, INC. | $14.80 | 2019 | |
| Sanara Medtech INC. | $14.71 | 2023 | Celleraterx |
| Assertio Therapeutics, INC. | $14.35 | 2020 | |
| Medartis INC. | $13.34 | 2020 | |
| Abbvie INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Trent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.